Q4 2025 Sanara Medtech Inc Earnings Call Transcript
Key Points
- Sanara MedTech Inc (SMTI) exceeded $100 million in net revenue for the first time, achieving $103.1 million for the full year 2025, marking a 19% year-over-year growth.
- The company improved its profitability profile, expanding gross margins by approximately 200 basis points to 93% for the full year 2025.
- Sanara MedTech Inc (SMTI) achieved a significant reduction in net loss from continuing operations by 80% and improved adjusted EBITDA by 86%, resulting in $17 million for the full year 2025.
- The company generated $6.8 million of cash from operations in 2025, a substantial increase compared to $24,000 used in operations in 2024.
- Sanara MedTech Inc (SMTI) expanded its network of distributor partners to over 450 contracted distributors by the end of 2025, up from over 350 in 2024, enhancing its commercial strategy.
- Operating expenses increased by 13% to $24.6 million in the fourth quarter of 2025, driven by a noncash impairment charge and increased R&D expenses.
- Net loss from continuing operations for the fourth quarter was $1.1 million, compared to net income of $0.9 million in the previous year.
- The company faced higher interest expenses and fees related to its CRG term loan, contributing to an increase in other expenses.
- Despite progress, surgeon penetration within the over 1,450 healthcare facilities served remains relatively low, indicating untapped potential.
- The wind-down of the Tissue Health Plus segment resulted in a cash use of $5.3 million over the second half of 2025, although this was below the initially projected range.
Welcome to the Sanara MedTech fourth quarter in full year 2025, earnings conference call. Please note that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly. The company issued its earnings release earlier today.
Before we begin, I would like to remind everyone that certain statements on today's call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risks and uncertainties.
Involving forward-looking statements and factors that could cause actual results to differ materially from those projected or implied by forward-looking statements, please see the risk factors set forth in the company's most recent annual report on Form 10-K.
This call will also include references to certain non-GAAP financial measures. Reconciliations of those non-GAAP measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings release available on the investor relations
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
